In a world where the pursuit of youth and longevity has become a lucrative industry, Everlab stands out with its principled approach to health and wellness. The company, led by CEO Marc Hermann, has made a bold statement by refusing to offer peptides, the anti-ageing compounds that have gained popularity among biohackers and influencers.
"We could be rolling in money with peptides," Hermann admits, "but safety comes first." This stance is a refreshing change in an industry often driven by profit, and it's a strategy Everlab hopes will set it apart as it expands its reach beyond the wealthy and health-obsessed.
Everlab's flagship program, which costs around $3000 annually, offers members a comprehensive suite of diagnostic tests, doctor consultations, and AI-generated health plans. Initially viewed as a luxury, the company has seen a shift in its customer base, with a more even gender split and an increasing number of older Australians seeking its services.
"It's not just about the 'bio-age' score," Hermann explains. "Our members want guidance and support to navigate their health, and that's where we excel."
However, not everyone is convinced. Professor Luigi Fontana, a leading longevity researcher, warns of the potential pitfalls of extensive health screening, citing concerns about incidental findings and the subsequent cascade of tests and anxiety they can trigger.
But Hermann remains steadfast in his commitment to evidence-based practices. Everlab operates as a GP practice, and its alignment with Medicare ensures a certain level of accountability.
"We're not here to peddle unproven treatments," Hermann asserts. "Our focus is on proper risk assessment and prevention."
This approach has garnered significant investment, with Everlab raising an impressive $65 million in its latest funding round. The company's valuation now stands at just under $500 million, a testament to the faith investors have in its unique model.
The funds will be used to expand into the UK and develop a corporate services arm, with high-profile clients already on board.
Everlab's success hinges on its ability to make preventative health accessible and desirable to the masses, rather than a privilege for the few. It's a bold vision, and one that could revolutionize the way we approach our well-being.
As Hermann puts it, "We're betting on a future where health is a right, not a luxury."
A future where companies like Everlab lead the way in ethical and evidence-based practices, ensuring that the pursuit of a longer, healthier life is not only achievable but also safe and sustainable.
